Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Including Patients With MYC Alterations
Phase of Trial: Phase II
Latest Information Update: 16 Oct 2017
At a glance
- Drugs CUDC 907 (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors Curis
- 14 Oct 2017 This trial has been completed in Germany.
- 21 Aug 2017 The trial has been suspended in Netherlands.
- 03 Aug 2017 According to a Curis media release, interim results from this trial have been published.